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Abstract
Background—Home-based, voluntary counseling and testing (HCT) presents a novel approach
to early diagnosis. We sought to describe uptake of pediatric HIV testing, associated factors, and
HIV prevalence among children offered HCT in Kenya.
Methods—The USAID-AMPATH Partnership conducted HCT in western Kenya in 2008.
Children 18 months to 13 years were offered HCT if their mother was known to be dead, her
living status was unknown, mother was HIV-infected or of unknown HIV status. This
retrospective analysis describes the cohort of children encountered and tested.
Results—HCT was offered to 2,289 children and accepted for 1,294 (57%). Children were more
likely to be tested if more information was available about a suspected or confirmed maternal
HIV-infection (for HIV-infected, living mothers OR=3.20, 95% CI: 1.64–6.23), if parents were
not in household (OR=1.50, 95% CI: 1.40–1.63), if they were grandchildren of head of household
(OR=4.02, 95% CI: 3.06–5.28), or if their father was not in household (OR=1.41, 95% CI: 1.24–
1.56). Of the eligible children tested, 60 (4.6%) were HIV-infected.
Conclusions—HCT provides an opportunity to identify HIV among high-risk children;
however, acceptance of HCT for children was limited. Further investigation is needed to identify
and overcome barriers to testing uptake.
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INTRODUCTION
In order to initiate timely HIV treatment and ensure widespread prevention of further
infections, a person must first know his or her HIV status.[1] Early diagnosis and treatment
is particularly important within pediatrics since HIV-infected children face very high
mortality rates in the first few years of life. Without treatment, approximately 50% of HIV-
infected children die before the age of 2, with mortality rates as high as 75% by 5 years of
age.[2, 3] In regions such as sub-Saharan Africa, where a high incidence of infection is
coupled with limited resources, the early diagnosis of HIV-infected children is critical for
optimal therapy and effective public health planning.[4]
Despite the critical importance of testing at-risk children for HIV, acceptance of pediatric
testing among caregivers and children in sub-Saharan Africa has not yet been well studied.
In a study of free inpatient HIV testing in Uganda, testing was offered to all adults and
children who were admitted to participating units in the hospitals and who had not had
previous HIV testing.[5] The overall uptake for testing was 98%, but this statistic was not
broken down by age, and does not specify children’s testing uptake. The prevalence of HIV
was 28% in the 39,037 patients who had never been tested before and 9% in those who had
previously tested negative.[5] Of the 10,439 family members offered testing, 9720 (93%)
accepted and 20% were HIV-infected.[5] Outpatient testing programs may differ from
inpatient testing programs in both the uptake of testing and prevalence of HIV. In evaluation
of a program offering HIV counseling and testing for outpatients seen at a rural hospital in
Tanzania, children constituted 6.6% of the 4,353 individuals tested.[6] 1069 (24.6%) of
those tested were HIV-infected, and 83 of these (7.8%) were children.[6] In a study of an
outpatient program in Malawi offering HIV testing with acute malnutrition care, 92% of the
children presenting for nutrition services also were tested for HIV and HIV prevalence was
3%.[7] In the inpatient setting of the same program, 97% of caregivers accepted HIV testing
for children admitted with malnutrition, and HIV prevalence was 21.6%.[8] The uptake of
testing in settings where patients also receive other forms of care or service may differ
significantly from the uptake of testing in the general community.
Community- or population-based HIV testing may allow identification of HIV-infected
children before they exhibit signs or symptoms of illness, enabling earlier treatment and
more effective prevention. One such approach is Home-Based Voluntary Counseling and
Testing (HCT).[9] The Academic Model Providing Access to Healthcare (AMPATH), is a
large clinical care system that has enrolled over 113,000 HIV-infected adult and pediatric
patients in western Kenya.[10] In 2007, AMPATH initiated HCT in western Kenya.[11]
AMPATH implemented a form of HCT that includes the administration of a rapid, in-home
HIV test for adults and children above 18 months, immediate disposition of the test results,
post-test counseling and appropriate referral -- all during one visit to a household.[12] In this
paper, we report the acceptance rates, associated characteristics, and results of HIV testing
for at-risk children 18 months to 12 years of age within a program of HCT implemented in
the Turbo Division in western Kenya.
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METHODS
Study Design
This retrospective study used data collected through the HCT initiative of the AMPATH
clinical care system in western Kenya. The study was approved by the Institutional Research
and Ethics Committee of the Moi University School of Medicine (Eldoret, Kenya) and the
Institutional Review Board of the Indiana University School of Medicine (Indianapolis,
Indiana).
Setting
AMPATH began in 2001 as a partnership between Moi University School of Medicine, Moi
Teaching and Referral Hospital (Eldoret, Kenya), and the Indiana University School of
Medicine (Indiana, United States).[13, 14] AMPATH currently provides comprehensive
HIV care, including free antiretroviral therapy, for over 101,000 HIV-infected and HIV-
exposed adult and pediatric patients in 23 clinics and 23 clinic satellites throughout western
Kenya.[13] AMPATH actively provides care for over 14,800 children under the age of 14
years (as of 15 May 2010).
AMPATH piloted implementation of HCT in the Kosirai Division of the Nandi North
District of the Rift Valley Province in 2007, and then rolled HCT out into the Turbo
Division of the Uasin Gishu District of the Rift Valley Province in 2008. This division is
considered representative of the ethnic groups and socioeconomic strata of many rural
divisions in western Kenya, and is the site of an AMPATH clinic caring for 5,340 patients,
including 989 children. Time constraints resulted in the implementation of two separate
phases of HCT in the Turbo Division, the first occurring June-December, 2008, and the
second in January-June, 2009. We examined data collected in the first phase of the Turbo
rollout, the first broad implementation of HCT in Kenya.
HCT Door-to-Door Program of Testing
AMPATH sought to establish a strong partnership with the target division in order to
effectively implement population-wide HCT in Turbo.[11] AMPATH conducted community
focus group discussions, and worked with community leaders to prepare for visits.
Mobilization teams, comprised of respected community members, disseminated information
about HIV,AMPATH’s services and the HCT program during visits to every household in
their respective villages. They also requested permission for trained counselors to
subsequently visit the home and offer counseling and testing for HIV.
All consenting, adult household members (those 13 years and older) were eligible for
testing. Children less than 13 years of age were deemed eligible for testing if they met one
or more of the following criteria: mother known to be dead; mother’s living status not
known; mother HIV-infected; or mother’s HIV status unknown. The mother’s HIV status
was determined through HCT testing or prior documentation of a positive HIV test. Parents/
guardians could also choose to have children who did not meet the eligibility criteria tested.
For children older than 18 months, HIV testing used parallel tests, the Determine HIV-1/2
rapid assay (Abbott Laboratories®) and SD Bioline HIV-1/2 3.0 rapid assay (Standard
Diagnostics Inc.®, Kyonggi-do, South Korea). If the results were discordant, a tie-breaking
test was done using the UniGold HIV test (Trinity Biotech®, Dublin, Ireland) rapid assay.
Post-test counseling was provided for everyone, and all children with positive test results
were referred to AMPATH. Children under 18 months of age require DNA PCR testing for
HIV because they may have circulating maternal antibodies in their blood, for which a rapid
test was not available. Thus, the parents or guardians of eligible children younger than
eighteen months of age received counseling and were referred to the AMPATH Turbo clinic
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for the children to have DNA PCR testing for HIV. Because testing for children under 18
months was not conducted within the immediate context of HCT, they were excluded from
the analyses. The parents and guardians of both HIV-infected and HIV-uninfected children
were counseled on risk-lowering behaviors, such as using condoms and repeated testing.
Data Collection and Measures
Personnel conducting HCT carried Palm T|X PDA devices (Palm Inc®, California, USA)
that were used to enter information into data-collection forms programmed with Pendragon
Forms Software (DDH Software, Inc®, Florida, USA). Data collected included individual
demographic and household information, as well as HIV testing results. Data were
transferred to a Microsoft Access database (Microsoft Corp®, Redman, Washington) by
synchronizing the PDAs to a dedicated server.
Data Analysis
We described the demographic and household characteristics of the cohort of children
approached in Phase One of Turbo HCT, focusing on acceptance of HIV testing and HIV
prevalence. We performed multivariable logistic regression to assess the association
between odds of accepting HIV testing for children and mother risk category, controlling for
gender, age, whether both parents were in the household, child’s relationship to head of
home, father’s HIV status, father’s living status, whether the child had been completely
immunized (by immunization card or by caregiver report), and whether the child had a
previous HIV test. Mother risk was defined as an ordered, categorical variable (0= Mother
HIV-uninfected and alive, 1 = Mother HIV-unknown and alive, 2= Mother HIV-uninfected
or HIV-unknown and living status unknown, 3 = Mother HIV-uninfected or HIV-unknown
and dead, 4 = Mother HIV-infected and alive, and 5 = Mother HIV-infected and dead or
living status unknown). We assessed whether a higher mother risk category was statistically
significantly associated with an increased odds of accepting HIV testing by including the
ordered categorical variable mother risk category as a continuous variable (test of trend).
Stratified analyses were done to determine whether sociodemographic characteristics were
differentially associated with the odds of accepting testing by mother risk category. We
tested the statistical significance of interactions using likelihood ratio tests. All models
calculated 95 percent confidence intervals based on robust variance estimates. All statistical
analyses were performed using Stata MP 10.1 for Windows (Stata Corp, College Station,
TX).
RESULTS
The HCT effort in the Turbo Division identified a total of 57,466 household residents. Of
these, 15,513 were children aged less than 13 years, and 12,862 were between the ages of 18
months and 13 years. 49.2% were female, and 88.6% had their parents in the household. Of
these 12,862 children, HCT was indicated for 2,289 children. (Figure 1)
Of the 2,289 children for whom testing was indicated, HIV testing was accepted for 1294
children (57%). (Figure 1) Among all children for whom testing was indicated, higher
percentages of children in the tested group did not have parents living with them; were
grandchildren of the head of household (compared to being children of the head of
household, other relatives of the head of household, or non-biological relations to the head
of household); had a father who had died, had living status was unknown, or was HIV-
infected; and had their immunization status was unknown. (Table 1) Higher percentages of
children ages 5 to 12 years had HIV testing than did children who were less than 5 years of
age. In multivariate logistic regression, eligible children were less likely to be tested for HIV
if their mother was alive and had an unknown HIV status (OR = 0.34, 95%CI: 0.18–0.66), if
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they lived with both parents (OR=0.50, 95% CI: 0.40–0.63), or if they had previously been
tested for HIV (OR=0.30, 95%CI: 0.19–0.46). Children were more likely to be tested if
more information was available about a suspected or confirmed maternal HIV-infection (for
HIV-infected, living mothers, OR=3.20, 95% CI: 1.64–6.23) or if they were not the child of
the head of household. For example, grandchildren of the head of household were more
likely to receive HIV testing (OR=4.02, 95% CI: 3.06–5.28). Children were more likely to
get tested if both of their parents were absent from the household (OR=1.50, 95% CI: 1.40–
1.63) or if their father was not in the household (OR=1.41, 95% CI: 1.24–1.56). Gender;
father’s HIV status; being related to the head of the household as a sibling, househelp, or
“other” relationship; child’s age; child’s immunization status; having a mother whose living
status and HIV status are unknown; and having a dead mother with unknown or negative
HIV status were not significantly associated with uptake of testing in the multivariable
logistic regression.
Of the 1,294 children for whom testing was indicated and whose parents/guardians accepted
testing, sixty (4.6%) of the children were HIV-infected. (Table 2) Positive HIV tests in
children were more common among the children with mothers known to be HIV-infected;
9% of the children with HIV-infected, living mothers tested positive and 13% of those with
HIV-infected, deceased or unknown living status mothers tested positive. (Table 2)
As previously described, the mother’s risk factors defined whether or not testing was
indicated for children. Parental/guardian acceptance of testing varied with the mother’s
specific risk factors within the general indication for testing (Table 3). The odds of accepting
testing for a child was increased with higher values of the mother risk variable, with p<0.001
for the test of trend. This remained significant even when excluding those children whose
mothers were alive and known to be HIV-uninfected and adjusting for the other variables (p
<0.01). Children whose mothers were alive but had unknown HIV status (N=1,283) were
more likely to be tested if they were older, if they did not have parents in the household, if
they were not the children of the head of the household, or if their fathers were dead or
living status was unknown. (Table 3) If their fathers were known to be HIV-uninfected, then
these children were less likely to be tested. Children who had deceased mothers or for whom
the mother’s living status was unknown and the mother’s HIV status was negative or
unknown (N=299) were more likely to be tested if they were older; if they did not have
parents in the household; if they were not the children of the head of household; if their
father’s HIV status was unknown; if their father had died or had an unknown living status,
or if the child’s immunization status was unknown.
Among children whose mothers were alive and HIV-infected (N=635), there were no
prominent differences in demographics between those who were tested and those who were
not, except that those not tested had more often had a previous HIV test and were less likely
to have known immunization status. (Table 3) The groups were similar in regard to gender;
age; the presence of parents in the household; relationship to the head of household; and
father’s HIV and living status. Among children whose mothers were dead or of unknown
living status but known to be HIV-infected (N=72), older children, children whose parents
were not in the household, those who were not the children of the head of the household,
children whose fathers had died, and children with unknown immunization status were
tested more often.
In 10,573 cases, HCT testing was not indicated for the children because the child’s mother
was both alive and HIV-uninfected. Children for whom testing was not indicated differed
from the children for whom testing was indicated in other ways besides having a living,
HIV-uninfected mother (Table 1). These children were also younger, more likely to have a
mother or a father in the household, and more likely to be children of the head of the
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household. They more often had living, HIV-uninfected fathers, and were described as fully
immunized. Thirty-two children for whom testing was not indicated had had a prior HIV test
(0.2%). Caregivers opted to have testing for 239 children for whom testing was not
indicated; one was found to be HIV-infected.
DISCUSSION
HCT provides a unique opportunity to identify HIV infection early in the disease course,
enabling the provision of early treatment and enhancing possibilities for prevention of
transmission. Implementation of HCT in the Turbo Division of western Kenya used the
mother’s risk factors, specifically HIV status and living status, to identify children at high-
risk for HIV infection. In contrast to the testing of adults in this program, where 95% of
adults accepted testing,[12] caregivers refused HIV testing for almost half of these high-risk
children, underscoring the need to improve home-based pediatric HIV testing. Children with
HIV-infected mothers, children who did not have parents in the household and those who
were not the children of the head of household were more likely to get HIV tests. Given the
rates of HIV among those who were tested, there may be many HIV-infected children who
remain undiagnosed if no community-based testing is available or if these testing options are
refused.
The findings underscored that maternal HIV and living status are key indicators of a child’s
HIV risk, both in terms of caregivers’ willingness to have the child tested and in terms of
HIV prevalence. As the mother’s risk factors increased, so did the likelihood of testing and
of HIV infection. The children of mothers known to have HIV infection and/or known to be
dead were most likely to be tested, and children with mothers known to be HIV-infected
were more likely to be HIV-infected as well. Many children with HIV-infected mothers did
remain untested, and these children had minimal differences in demographic characteristics
from those with HIV-infected mothers who were tested. Thus, it is possible that HIV
diagnoses were missed among the children for whom testing was refused. If all children who
were considered high risk for HIV had been tested and if they had had an equal risk of HIV
infection as the other children who were tested, 46 (2%) more pediatric HIV cases may have
been identified.
This study found that almost half of caregivers did not consent to have high-risk children
tested for HIV in HCT. The acceptance of testing varied with the child’s position in the
household, in particular with their relationship to the head of household and whether or not
their fathers were alive or HIV-infected. Children who did not have both parents in the
household and who were not the children of the head of the household were more likely to
get tested. This suggests that orphaned children living with extended family may be more
likely to be tested for HIV than children still living with their biological parents. This could
reflect that the caregivers of these children are less concerned about the stigma associated
with HIV testing or the child’s HIV status. Biological caregivers also may not consent to
testing because of feelings of guilt over potentially being the source of the child’s infection.
Children with an HIV-infected or deceased father may have been tested more often because
they were seen as being at greater risk for HIV given their father’s potential or known HIV
status or the possibility that the father may have died from HIV. There was also a trend for
older children to be more likely to get tested. Parents may be more apt to test older children
for multiple reasons: older children manifesting more illnesses or signs of infection with
age, concerns about increasing risk of transmitting infection as sexual debut draws closer, or
feeling that an older child is better able to handle the diagnosis psychologically and
emotionally. This would be in line with previous research, where caregivers refused testing
for children because of fear that they were not psychologically ready or because the children
were still healthy.[7] With increased antenatal HIV testing, it is also possible that younger
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children and their mothers were more likely to have received antenatal counseling and
testing previously. Having previous testing was a reason for not accepting another HIV test
described for both adults and children in the study of inpatient HIV testing in Uganda.[15]
Fear of stigma and discrimination in the community also may have played a role in the
refusal of testing. Because testing was only offered to high-risk children, and not to every
child in every household, parents and caregivers may have been afraid that accepting testing
for the children would signal to their neighbors that the household had some risk factor for
HIV. In this setting, parents often avoid informing children about their HIV diagnosis or
keep HIV medicines hidden because they are afraid the child will tell others.[16] Similarly,
fear that the child would report that they were tested could have influenced parents’
willingness to accept the testing. Alternatively, individual, family, or community factors not
measured by this program may have influenced testing. For example, the acceptance of
testing for children may be related to perception of access to care, or to varying experiences
of clinical disease in the mother or child.
These outcomes underscore the need to further investigate caregivers’ reasons for refusing
pediatric testing so that we do not miss important opportunities to detect HIV within high-
risk pediatric populations. More open-ended or qualitative techniques may be needed to
illuminate the impact of social stigma; beliefs about pediatric HIV acquisition, treatment, or
prognosis; issues about consenting for children’s testing; concerns about the emotional
impact of testing positive; or logistic challenges to pediatric testing and care access. Better
understanding caregiver rationales for refusing or accepting testing will help identify
interventions to increase pediatric testing uptake and ultimately improve treatment and
prevention.
There are several potential limitations to our study. One limitation is that children were
considered eligible or not eligible for testing based on the characteristics of their mother. A
child’s own risk factors or their health status were not taken into account, nor was the testing
aimed universally for all child household members as it was for adult household members.
Whether or not a child was sick or other characteristics about the child may have offered
appropriate criteria for offering testing that also may have influenced caretakers’ decisions.
Nonetheless, the maternal characteristics clearly did play an important role in determining at
risk children. Another limitation is that we were unable to offer testing for the youngest
children, those under 18 months of age, who are also the most in need of early treatment if
HIV-infected. These children could not be tested within their homes because of the need for
a non-rapid, DNA PCR test to distinguish maternal antibodies from child antibodies.
Prevalence of HIV among these children and follow-up of testing uptake with the need for a
specialized referral would be interesting outcomes, but are not data captured in the scope of
this investigation. Another limitation is that some households in the target community, and
some individuals within the households, were missed during the “Turbo Phase One” testing
and approached and possibly tested during “Phase Two”. Nonetheless, there was no
indication of any selection bias in who was recruited in each phase. Moreover, Phase One
data still reflect a large community sample, with over 57,000 household residents counseled
and offered testing. Another potential limitation is that our analyses were limited to
quantitative data collected during brief household visits. While additional individual or
household characteristics may have been of interest, we could only examine the data
recorded. A final limitation of this study is that it occurred in a specific geographical and
cultural area, which may not be generalizable to other regions. However, as other resource-
limited settings move to scale-up HIV testing for larger populations and using community-
based approaches, these results underscore the importance of considering how uptake of
pediatric testing can be maximized for this vulnerable population.
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In conclusion, home-based counseling and testing offers an important method for identifying
the HIV-infected children early in their disease course. Maximizing the uptake of pediatric
HIV testing for this vulnerable population will ensure optimal therapy and effective public
health interventions to prevent transmission. While we were able to test almost 1,300
children and to identify 60 new pediatric HIV cases through HCT in a single community,
HIV testing was not accepted for almost half of the high-risk children to whom testing was
offered. In addition to the mother’s HIV status and living status, whether or not the children
had parents in the household and their relationship to the head of the household appeared to
play an important role in whether their caregivers accepted HIV testing for the children.
When parents or guardians refuse to test even high-risk children for HIV, urgent attention
needs to be paid to identifying the caregivers’ barriers to pediatric testing and overcoming
these barriers.
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Figure 1.
Flow Diagram for Acceptance of Pediatric Testing Through HCT in Turbo, Kenya.
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Table 2
HIV Test Results Among Children Tested in HCT
HIV Negative HIV Positive
Group based on Mother Risk N % of group N % of group
Mother: HIV unknown and alive 579 99.1% 5 0.9%
Mother: HIV-uninfected or unknown and living status unknown 52 100.0% 0 0.0%
Mother: HIV-uninfected or unknown and dead 132 95.7% 6 4.3%
Mother: HIV-infected and alive 424 91.0% 42 9.0%
Mother: HIV-infected and dead or unknown 47 87.0% 7 13.0%
Total among those tested 1234 95.8% 60 4.7%
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Optional Table
Adjusted odds of accepting pediatric HIV testing by demographics.
Odds Ratio 95% Confidence
Intervals
Mother HIV unknown and alive 0.34 0.18–0.66
Mother HIV negative or unknown and living status unknown 0.91 0.39–2.15
Mother HIV negative or unknown and dead 0.55 0.27–1.11
Mother HIV positive and alive 3.20 1.64–6.23
Male 0.88 0.73–1.06
Age
   2yr – 2yr11mo 0.96 0.61–1.53
   3yr – 3yr11mo 1.10 0.70–1.73
   4yr–4yr11mo 1.44 0.90–2.30
   5yr – 5yr11mo 1.10 0.43–2.80
   6yr – 6yr11mo 1.65 0.64–4.27
   7yr – 7yr11mo 1.44 0.55–3.73
   8yr – 8yr11mo 1.09 0.43–2.79
   9yr – 9yr11mo 1.48 0.57–3.87
   10yr – 10yr11mo 1.49 0.58–3.85
   11yr – 11yr11mo 2.03 0.77–5.38
   12yr – 12yr11mo 1.54 0.59–4.02
Both parents in household 0.50 0.40–0.63
Father not in household 1.41 1.24–1.56
Child’s relationship to head of household
   Child Reference
   Grandchild 4.02 3.06–5.28
   Sibling 1.03 0.52–2.05
   Foster child or step child 4.35 2.26–8.40
   Niece, nephew, or cousin 4.11 2.41–7.01
   Househelp, employee 2.01 0.57–7.07
   Other 2.50 0.88–7.08
   Missing 1.91 0.73–5.02
Father HIV positive 0.80 0.53–1.21
Father’s HIV status unknown 0.58 0.44–0.76
Father dead 0.99 0.72–1.36
Father’s living status unknown 0.90 0.66–1.22
Child immunized 0.65 0.22–1.85
Child’s immunization record unknown 0.76 0.20–2.84
Previously tested 0.30 0.19–0.46
Notes: Bold indicates statistical significance. Variables of child’s age 18mo – <24mo and Mother HIV positive & mother dead or living status
unknown dropped because of collinearity.
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